Second jab of COVID-19 vaccine should not be delayed for cancer patients: report – National


Delayed administration of the second dose of an mRNA COVID-19 vaccine leaves most cancer patients unprotected, a new report warns.

In clinical trials last year, the messenger RNA vaccines were tested with second doses given either three or four weeks after the first depending on the vaccine.

Read more:
Canada saw over 13,000 ‘excess deaths’ during 1st year of COVID-19: StatCan

In January, the UK decided to delay second doses until 12 weeks. At Kings College London, doctors studied 205 adults who received the Pfizer/BioNTech vaccine, including 151 cancer patients.

After the first dose, almost all the healthy individuals had strong immune responses, but that was true for fewer than half of patients with solid tumors and fewer than one-in-seven patients with blood cancers, said Dr. Adrian Hayday.

Story continues below advertisement


Click to play video 'Doctors concerned that patients may be delaying cancer treatment during COVID-19 pandemic'



Doctors concerned that patients may be delaying cancer treatment during COVID-19 pandemic


Doctors concerned that patients may be delaying cancer treatment during COVID-19 pandemic – Feb 4, 2021

When solid-cancer patients got the second dose at the recommended three weeks, 95 per cent developed robust antibody responses.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

Among those who did not get the booster dose on time because of the UK’s new policy, only 43 per cent of solid cancer patients and eight per cent of blood cancer patients had antibodies at five weeks.

Read more:
What we have learned about treating COVID-19 one year into the pandemic

“A single dose of the vaccine left most cancer patients largely or completely unprotected,” Hayday said.

The study report has been submitted ahead of peer review to medRxiv but is not yet online. The data are available on the COVID-Immuno-Phenotype website.






Source link

SHARE ME PLEASE!
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Leave a Reply